( nced the reduction in tumor volume prod...)Spectrum Pharmaceuticals Announces Data From Three Oncology,Programs Presented at the American Association of Cancer Research,Annual Meeting,Health

nced the reduction in tumor volume produced by cyclophosphamide and cisplatin. There was a 130 percent, 65 percent and 70 percent decrease in the tumor volume of animals administered with SPI (IRL)-1620 plus cyclophosphamide as compared to cyclophosphamide alone on day 10, 16 and 22, respectively. Similarly, the reduction in tumor volume in SPI (IRL)-1620 plus cisplatin treated animals was 31 percent, 68 percent and 80 percent greater on day 10, 16 and 22, respectively compared to cisplatin alone treated animals.

Conclusion

In conclusion, SPI (IRL)-1620 significantly enhanced the efficacy of cyclophosphamide and cisplatin in a preclinical model of ovarian tumor in mice.

About EOquin

EOquin (apaziquone for intravesical instillation) is a drug currently being developed for the treatment of non-invasive bladder cancer, which is a cancer that has invaded the inner most lining of the bladder. EOquin, an anti-cancer agent that becomes activated by reductase enzymes found in cancer cells, is formulated for administration directly into the urinary bladder. In a Phase 2 pilot study for which patient accrual was completed this year, EOquin instilled into the bladder following TUR-BT was well tolerated and was not absorbed in any detectable amount from the bladder wall into the bloodstream and therefore, would carry a low risk of harming the rest of the body.

Spectrum Pharmaceuticals completed a multi-center, Phase 2 clinical trial in Europe. The results of the trial showed that EOquin was well-tolerated and produced 67% CRs (complete responses) in patients, many of whom had been treated multiple times. EOquin received a Special Protocol Assessment from the U.S. Food and Drug Administration (FDA) for non-invasive bladder cancer and the Company expects to begin enrollment of the first patients in the Phase 3 trial this quarter.

About Satraplatin

Satraplatin, a fourth-generation, oral investigational drug, is a member of the plati
'"/>

Page: 1 2 3 4 5 6 7 8
Related medicine technology :

1. Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of Erbitux for Colorectal and Head and Neck Cancer Patients
2. AEterna Zentaris Partner, Spectrum, Discloses Detailed Phase 2 Data for Ozarelix, in BPH at Annual AUA Meeting
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)